Korro Bio
16 articles with Korro Bio
-
Korro Bio and Genevant Sciences Enter into Collaboration Agreement to Develop RNA Editing Therapeutic for Alpha-1 Antitrypsin Deficiency
3/7/2023
Korro Bio and Genevant Sciences today announced that they have entered into an agreement to combine Korro’s powerful RNA editing platform with Genevant’s industry-leading LNP technology to develop a differentiated therapeutic option for patients with Alpha-1 Antitrypsin Deficiency (AATD).
-
Korro Bio Appoints Dr. Steve Colletti as Chief Scientific Officer
2/28/2023
Korro Bio, Inc ., a leading RNA editing company focused on the discovery and development of novel genetic medicines, today announced the appointment of Steve Colletti, Ph.D. as Chief Scientific Officer.
-
Korro Bio to Present at the 41st Annual J.P. Morgan Healthcare Conference
1/4/2023
Korro Bio, Inc., a leading RNA editing company focused on the discovery and development of novel genetic medicines, announced that Ram Aiyar, Ph.D., MBA, Chief Executive Officer and President, will present at the 41st Annual J.P. Morgan Healthcare Conference, being held January 9-12, 2023 in San Francisco, CA.
-
While Biogen and Seagen made the biggest C-suite splashes this week, other companies across the biopharma industry also bolstered their leadership teams with new talent.
-
Korro Bio Expands Leadership Team with Key Appointments
11/8/2022
Korro Bio, Inc today announced the appointment of Venkat Krishnamurthy, Ph.D., as Senior Vice President, Head of Platform and Stephanie Engels as Senior Vice President, Head of People and Culture.
-
Korro Bio to Participate in 2022 Jefferies Healthcare Conference
6/6/2022
Korro Bio, Inc. announced that Ram Aiyar, Ph.D., MBA, Chief Executive Officer, will present at the 2022 Jefferies Healthcare Conference, being held in New York, NY, on Thursday, June 9, 2022, at 10:30 a.m. EDT.
-
Korro Bio to Present at the 40th Annual J.P. Morgan Healthcare Conference
1/5/2022
Korro Bio to Present at the 40th Annual J.P. Morgan Healthcare Conference.
-
Korro Bio Completes $116M Series B Financing to Expand the Frontier of Genetic Medicine Through Its Pipeline of RNA Editing Programs
1/5/2022
Financing led by Eventide Asset Management with participation from a strong syndicate of new and existing investors.
-
With the beginning of a new year, many biopharmaceutical companies are reporting financial raises to advance their pipelines. BioSpace takes a quick look at some of them.
-
Korro Bio to Present at the Evercore ISI 4th Annual HealthCONx Conference and the Piper Sandler 33rd Annual Virtual Healthcare Conference
11/22/2021
Korro Bio to Present at the Evercore ISI 4th Annual HealthCONx Conference and the Piper Sandler 33rd Annual Virtual Healthcare Conference.
-
Korro Bio Chief Executive Officer Ram Aiyar, Ph.D., MBA, to Present at 2021 Jefferies Virtual Healthcare Conference
5/25/2021
Korro Bio, Inc. , an RNA editing company focused on the discovery and development of novel genetic medicines, today announced that Ram Aiyar, Ph.D., MBA, chief executive officer, will present at the 2021 Jefferies Virtual Healthcare Conference on June 4, 2021, at 2:30 p.m. EDT.
-
Korro Bio Appoints Vineet Agarwal as Chief Financial Officer
5/11/2021
Korro Bio, Inc ., an RNA editing company focused on the discovery and development of novel genetic medicines, today announced the appointment of Vineet Agarwal as Chief Financial Officer.
-
Korro Bio Strengthens Leadership Team With Appointment of Howard Stern M.D., Ph.D. as Chief Scientific Officer
4/1/2021
Korro Bio, Inc. , an RNA editing company focused on the discovery and development of novel genetic medicines, today announced the appointment of Howard Stern, M.D., Ph.D. as Chief Scientific Officer. Dr. Stern is a seasoned biotechnology executive with extensive experience in drug discovery and development,
-
Korro Bio Chief Executive Officer Ram Aiyar, Ph.D., MBA, to Present at Upcoming Conferences
3/5/2021
Korro Bio, Inc. , a biotechnology company developing single-base RNA editing therapies, today announced that Ram Aiyar, Ph.D., MBA, chief executive officer, will present at the Barclays Global Healthcare Conference and the WuXi Healthcare Forum this month.
-
Korro Bio to Present at J.P. Morgan Healthcare Conference
1/7/2021
Korro Bio, Inc. , a biotechnology company developing single-base RNA editing therapies, today announced that Ram Aiyar, Ph.D., MBA, chief executive officer, will present an update on Korro’s progress at the 39 th Annual J.P. Morgan Healthcare Conference. The presentation will take place on Thursday, January 14, 2021 at 8:05 a.m. E.T. using a virtual platform. About Korro Bio, Inc. Korro is leading the
-
BioSpace is proud to present its NextGen Bio “Class of 2021,” a list of up-and-coming life science startups in North America that recently launched.